{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91.60","upperLimit":"100.00","value":"98.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.81","upperLimit":"99.04","value":"95.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"}],"units":"Participants"}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.98","upperLimit":"97.28","value":"92.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"}],"units":"Participants"}],"description":"Sensitivity (True Positive rate) measures the proportion of positives that are correctly identified (i.e., the proportion of those who have some condition (affected) who are correctly identified as having the condition).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with presumptive radiologic evidence of prostate cancer recurrence or metastasis on conventional imaging and planned for conventional image-guided biopsy were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection.","id":"OG000","title":"Recurrent or Metastatic Prostate Cancer (Cohort B)"}],"paramType":"NUMBER","populationDescription":"Participants with recurrent or metastatic prostate cancer who received 18F-DCFPyL, underwent a conventional image-guided biopsy, and provided an 18F-DCFPyL PET/CT image result and a corresponding histopathology result, along with a conventional image that confirmed the location of the histopathology sample.","reportingStatus":"POSTED","timeFrame":"Within 28 days of 18F-DCFPyL PET/CT imaging, conventional image-guided biopsy occurred.","title":"Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Prostate Cancer Within Sites of Metastasis or Local Recurrence Relative to Histopathology in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}